{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:47:31Z","timestamp":1780602451604,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>National Comprehensive Cancer Network HCC guidelines recommend Y90 to treat BCLC-C patients only in select cases given the development of systemic regimens. We sought to identify ideal candidates for Y90 by assessing survival and toxicities in this patient group.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>The Radiation-Emitting Selective Internal radiation spheres in Non-resectable tumor registry is a prospective observational study (NCT: 02,685,631). Patients with advanced HCC were stratified into 3 groups based on tumor location, Eastern Cooperative Oncology Group (ECOG) performance status, and liver function. Group 1: liver isolated HCC, ECOG 0 and Child Pugh (CP) A (<jats:italic>n<\/jats:italic>\u2009=\u200912, 16%), Group 2: liver isolated HCC, ECOG\u2009\u2265\u20091 or CP B\/C (<jats:italic>n<\/jats:italic>\u2009=\u200937, 49%), and Group 3: extrahepatic HCC with any ECOG or CP score (<jats:italic>n<\/jats:italic>\u2009=\u200926, 35%). Patients in any group could have macrovascular invasion. Overall survival (OS) and progression-free survival (PFS) with 95% confidence intervals (95% CI) were calculated. Grade 3\u2009+\u2009toxicities were tracked using Common Terminology Criteria for Adverse Events v5. Cox proportional hazard model was performed to determine factors affecting OS.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventy-five BCLC-C patients treated between 2015 and 2019 were reviewed. The groups were similar in age, sex, race, and ethnicity (all <jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Bilobar disease was least common in Group 1 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Median OS of the entire cohort was 13.6 (95% CI 7.5\u201316.1) months. Median OS of Groups 1\u20133 were 21.8, 13.1 and 11.5\u00a0months respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.6). Median PFS for the cohort was 6.3 (4.8\u201314.7) months. Median PFS for group 1 was not reached. Mean PFS for Group 1 was 17.3\u2009\u00b1\u20094.8\u00a0months. Median PFS for Groups 2 and 3 was 6.8 and 5.9\u00a0months (X<jats:sup>2<\/jats:sup>\u2009=\u20091.5, <jats:italic>p<\/jats:italic>\u2009=\u20090.5). Twenty-four Grade 3 or greater toxicities developed, most commonly hyperbilirubinemia (8\/75, 11%) and thrombocytopenia (2\/75, 3%). The incidence of toxicities between groups was similar (all <jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Cox Proportional Hazard analysis predicted shorter OS with CP class B\/C (X<jats:sup>2<\/jats:sup>\u2009=\u20096.7, <jats:italic>p<\/jats:italic>\u2009=\u20090.01), while macrovascular invasion (X<jats:sup>2<\/jats:sup>\u2009=\u20090.5, <jats:italic>p<\/jats:italic>\u2009=\u20090.5) and ECOG score of\u2009\u2265\u20091 (X<jats:sup>2<\/jats:sup>\u2009=\u20092.1, <jats:italic>p<\/jats:italic>\u2009=\u20090.3) was not associated with OS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>OS of CPA patients with advanced HCC and performance status of 0 was 21.8\u00a0months following Y90. CP A cirrhosis is the best predictor of prolonged OS in advanced (BCLC-C) HCC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-022-02528-y","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T12:03:54Z","timestamp":1668686634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C)"],"prefix":"10.1186","volume":"22","author":[{"given":"Pulak","family":"Goswami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oladapo R.","family":"Adeniran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"K. Frantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ripal T.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary S.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"Matrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Petroziello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayson S.","family":"Brower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.","family":"Sze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jafar","family":"Golzarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"issue":"1","key":"2528_CR1","first-page":"335","volume":"159","author":"M Arnold","year":"2020","unstructured":"Arnold M, Abnet C, Neale R, Vignat J, Giovannucci E, McGlynn K, Bray F. Global burden of 5 major types of gastrointestinal cancer. World Health Organ. 2020;159(1):335-349.e15.","journal-title":"World Health Organ"},{"key":"2528_CR2","doi-asserted-by":"crossref","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM , Pineros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer, 2019; pp. 1941\u20131953.","DOI":"10.1002\/ijc.31937"},{"key":"2528_CR3","unstructured":"Globocan 2020. Section of cancer surveillance, international agency for research on cancer, World Health Organization; 2020. [Online]. Available: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/11-Liver-fact-sheet.pdf. [Accessed 17 March 2022]."},{"issue":"5","key":"2528_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","volume":"19","author":"BA Benson","year":"2021","unstructured":"Benson BA, D\u2019Angelica IM, Abbott DE, Anaya DA, Anders R, Are C, Bachini M, Borad M, Brown D, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Nat Compr Cancer Netw JNCCN. 2021;19(5):541\u201365.","journal-title":"J Nat Compr Cancer Netw JNCCN"},{"issue":"9319","key":"2528_CR5","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchard J, Richard S, Rodes J, Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734\u20139.","journal-title":"Lancet"},{"issue":"4","key":"2528_CR6","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/hep.29691","volume":"68","author":"R Salem","year":"2018","unstructured":"Salem R, Gabr A, Riaz A, Mora R, Ali R, Abecassis M, Hickey R, et al. (2018) \u201cInstitutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience.\u201d Hepatology. 2018;68(4):1429\u201340.","journal-title":"Hepatology"},{"issue":"6","key":"2528_CR7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jvir.2021.03.535","volume":"32","author":"S Frantz","year":"2021","unstructured":"Frantz S, Matsuoka L, Vaheesan K, Petroziello M, Golzarian J, Wang E, Gandhi R, Collins Z, Brower J, Rachakonda VM, Du L, Kennedy AS, Sze DY, Lee J, Brown DB. multicenter evaluation of survival and toxicities of hepatocellular carcinoma following radioembolization: analysis of the RESiN registry. J Vasc Interv Radiol JVIR. 2021;32(6):845\u201352.","journal-title":"J Vasc Interv Radiol JVIR"},{"issue":"2","key":"2528_CR8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s00270-017-1791-1","volume":"41","author":"R Ali","year":"2018","unstructured":"Ali R, Gabr A, Abouchaleh N, Al Asadi A. Survival analysis of advanced HCC treated with radioembolization: comparing impact of clinical performance status versus vascular invasion\/metastases. Cardiovasc Interv Radiol. 2018;41(2):260\u20139.","journal-title":"Cardiovasc Interv Radiol"},{"issue":"20","key":"2528_CR9","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Gale PR, Ducreux M, Kim T-Y, Kudo M, Breder V, Merele P, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"1","key":"2528_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T, Park J-W, Finn R, Cheng A-L, Mathurin P, Edeline J, Kudo M, Harding JJ, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77\u201390.","journal-title":"Lancet Oncol"},{"issue":"10126","key":"2528_CR11","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Shukui Q, Han K-H, Ikeda K, Piscaglia F, Baron A, Park J-W, Han G, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"21","key":"2528_CR12","first-page":"02241","volume":"S0168\u20138278","author":"A-L Chend","year":"2021","unstructured":"Chend A-L, Qin S, Ikeda M, Gale PR, Ducreus M, Kin T-Y, Lim HY, Kudo M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2021;S0168\u20138278(21):02241\u20138.","journal-title":"J Hepatol"},{"issue":"19","key":"2528_CR13","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow PKH, Gandhi M, Tan S-B, Khin MW, Khasbazar A, Ong J, Choo SP, Cheow PC, Chotipanich C, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in asia-pacific patients with hepatocellular carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(19):1913\u201321.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"2528_CR14","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E, Gui B, Ilonca AD, Pageaux G-P, Sibert A, Bouattour M, Lebtahi R. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624\u201336.","journal-title":"Lancet Oncol"},{"key":"2528_CR15","doi-asserted-by":"crossref","unstructured":"Ricke J, Klumpen HJ, Amthauer H et al., Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma, J Hepatol, pp. 1164\u20131174; 2019.","DOI":"10.1016\/j.jhep.2019.08.006"},{"key":"2528_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2021.06.003","author":"A Facciorusso","year":"2022","unstructured":"Facciorusso A, Paolillo R, Tartaglia N, et al. Efficacy of combined transarterial radioembolization and sorafenib in the treatment of hepatocarcinoma: a meta-analysis. Dig Liver Dis. 2022. https:\/\/doi.org\/10.1016\/j.dld.2021.06.003.","journal-title":"Dig Liver Dis"},{"issue":"6","key":"2528_CR17","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"European Association for the Study of the Liver","year":"2016","unstructured":"European Association for the Study of the Liver. European association for the study of diabetes and european association for the study of obesity, \u201cEASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease,.\u201d J Hepatol. 2016;64(6):1388\u2013402.","journal-title":"J Hepatol"},{"issue":"4","key":"2528_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.21037\/hbsn-20-480","volume":"9","author":"D-Y Xie","year":"2020","unstructured":"Xie D-Y, Ren Z-G, Zhou J, et al. Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"5","key":"2528_CR19","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1002\/hep.26014","volume":"57","author":"V Mazzafero","year":"2013","unstructured":"Mazzafero V, Spostio C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchiano A, Bongini M, Lanocita R, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013;57(5):1826\u201337.","journal-title":"Hepatology"},{"issue":"4","key":"2528_CR20","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s00259-013-2674-6","volume":"41","author":"C Spreafico","year":"2014","unstructured":"Spreafico C, Maccauro M, Mazzaferro V, Chiesa C. The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization. Eur J Nucl Med Mol Imaging. 2014;41(4):634\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2528_CR21","first-page":"348","volume":"32","author":"L Bolondi","year":"2012","unstructured":"Bolondi L, Burroughs A, Dufour J-F, Gale PR, Mazzaferro V, Piscaglia F, Raoul JL, Sangro B. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32(4):348\u201359.","journal-title":"Semin Liver Dis"},{"issue":"5","key":"2528_CR22","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1118\/1.3702457","volume":"39","author":"G Compagnone","year":"2012","unstructured":"Compagnone G, Gimpalma E, Domenichelli S, et al. Calculation of conversion factors for effective dose for various interventional radiology procedures. Med Phys. 2012;39(5):2491\u20138.","journal-title":"Med Phys"},{"key":"2528_CR23","doi-asserted-by":"crossref","unstructured":"Padia SA, Lewandowski RJ, Johnson GE, et al. Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions. J Vasc Interv Radiol 2017;28(1):1\u201315.","DOI":"10.1016\/j.jvir.2016.09.024"},{"issue":"9","key":"2528_CR24","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1007\/s00330-018-5393-3","volume":"28","author":"F Tovoli","year":"2018","unstructured":"Tovoli F, Renzulli M, Negrini G, et al. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib. Eur Radiol. 2018;28(9):3611\u201320.","journal-title":"Eur Radiol"},{"key":"2528_CR25","doi-asserted-by":"crossref","unstructured":"Choi JW, Kim H-C, Lee J-H et al. Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. Eur Rad, pp. 1148\u20131458; 2017.","DOI":"10.1007\/s00330-016-4511-3"},{"issue":"10","key":"2528_CR26","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.14309\/ajg.0000000000000715","volume":"115","author":"ND Parikh","year":"2020","unstructured":"Parikh ND, Singal AG, Hutton DW, Tapper EB. Cost-Effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms. Am J Gastroenterol. 2020;115(10):1642\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2528_CR27","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.2214\/AJR.21.26735","volume":"218","author":"DT Fetzer","year":"2022","unstructured":"Fetzer DT, Browning T, Xi Y, et al. Associations of ultrasound LI-RADS visualization score with examination, sonographer, and radiologist factors: retrospective assessment in over 10,000 examinations. Am J Roentgenol. 2022;218(6):1010\u201320.","journal-title":"Am J Roentgenol"},{"issue":"4","key":"2528_CR28","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jhep.2019.12.001","volume":"72","author":"HJ Park","year":"2020","unstructured":"Park HJ, Jang HY, Kim SY, et al. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: comparison with ultrasound. J Hepatol. 2020;72(4):718\u201324.","journal-title":"J Hepatol"},{"issue":"1","key":"2528_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/jgh.13150","volume":"31","author":"M Renzulli","year":"2016","unstructured":"Renzulli M, Golfieri R, Bologna Liver Oncology Group. Proposal of a new diagnostic algorithm for hepatocellular carcinoma based on the Japanese guidelines but adapted to the Western world for patients under surveillance for chronic liver disease. J Gastroenterol Hepatol. 2016;31(1):69\u201380.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"2528_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12876-022-02204-1","volume":"22","author":"A Mahvash","year":"2022","unstructured":"Mahvash A, Chartier S, Mark T, et al. A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of 90 Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study. BMC Gastroenterol. 2022;22(1):151.","journal-title":"BMC Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02528-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02528-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02528-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T12:13:06Z","timestamp":1668687186000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02528-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2528"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02528-y","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]},"assertion":[{"value":"26 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was approved and reviewed by the Vanderbilt Ingram Cancer Center and Vanderbilt University Institutional Review Board (IRB) as GI 1523 (IRB number 150407) and subsequently approved at the other sites.All patients signed informed consent to participate. This study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publications"}},{"value":"Ripal T. Gandhi is a consultant and speaker for Sirtex Medical and serves as a proctor for Sirtex Medical. Zachary S. Collins has received an institutional research grant from Sirtex Medical and serves as a speaker and consultant for Sirtex Medical. Jayson S. Brower is a consultant for Sirtex Medical. Daniel Y. Sze has received institutional research grants from Sirtex Medical and Boston Scientific. He was a consultant and has received support for travel\/hotel\/meals for meetings with Sirtex Medical and Boston Scientific. Andrew S. Kennedy has received institutional support from Sirtex Medical. Jafar Golzarian is a consultant for Sirtex Medical and Boston Scientific. He has also received institutional grant support from Sirtex Medical. Eric A. Wang is a proctor for Sirtex Medical. Daniel B. Brown has received institutional research support from Sirtex Medical and Guerbet. He has served as a speaker for Cook Medical and a Data Safety Monitor for Bard Medical. The other authors do not have a conflict to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"467"}}